SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
SCHEDULE
13G
(Rule
13d-102)
INFORMATION
TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES
13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED
PURSUANT
TO RULE 13d-2
(Amendment
No.__________)
*
Hypertension
Diagnostics, Inc.
--------------------------------------------------------------------------------
(Name of
Issuer)
Common
Stock, $.01 par value
--------------------------------------------------------------------------------
(Title of
Class of Securities)
44914V 10
4
-------------------------------------------------------------------------------
(CUSIP
Number)
December
31, 2008
--------------------------------------------------------------------------------
(Date
of Event Which Requires Filing of this Statement)
Check
the appropriate box to designate the
rule pursuant to which this Schedule is filed:
[_] Rule
13d-1(b)
[X] Rule
13d-1(c)
[
] Rule 13d-1(d)
----------
|
*
|
The remainder of
this cover page shall be
filled out for
a reporting
|
|
|
person's initial filing
on this form with respect to the subject class
of
|
|
|
securities, and
for any subsequent amendment containing information
which
|
|
|
would
alter the disclosures provided in a prior cover
page.
|
The information required
in the remainder of this cover page shall not be deemed to be
"filed" for the purpose of Section 18 of
the Securities Exchange Act of 1934 or
otherwise subject to the liabilities of that section of
the Act but shall be subject to all
other provisions of the
Act (however, see the Notes).
CUSIP
No. 44914V 10
4 13G Page
2 of 5 Pages
________________________________________________________________________________
1. NAME
OF REPORTING PERSONS
Marten Hoekstra
________________________________________________________________________________
2. CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [_]
(b) [_]
________________________________________________________________________________
3. SEC
USE ONLY
________________________________________________________________________________
4. CITIZENSHIP
OR PLACE OF ORGANIZATION
USA
________________________________________________________________________________
NUMBER
OF
5. SOLE VOTING POWER
SHARES
6,124,027
_________________________________________________________________
BENEFICIALLY
6. SHARED VOTING POWER
OWNED
BY 0
_________________________________________________________________
EACH
7. SOLE DISPOSITIVE POWER
REPORTING
6,124,027
_________________________________________________________________
PERSON
8. SHARED DISPOSITIVE POWER
WITH
0
________________________________________________________________________________
9. AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
6,124,027
SHARES (see explanation in Item 4)
________________________________________________________________________________
10. CHECK
IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE
INSTRUCTIONS)
[ ]
________________________________________________________________________________
11. PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
12.1%
________________________________________________________________________________
12. TYPE
OF REPORTING PERSON*
IN
________________________________________________________________________________
CUSIP No.
44914V 10
4 13G Page
3 of 5 Pages
________________________________________________________________________________
Item
1(a). Name of Issuer:
Hypertension
Diagnostics, Inc.
________________________________________________________________________________
Item
1(b). Address of Issuer's Principal Executive Offices:
2915
Waters Road, Suite 108, Eagan, MN 55121
________________________________________________________________________________
Item
2(a). Name of Person Filing:
Marten
Hoekstra
________________________________________________________________________________
Item
2(b). Address of Principal Business Office, or if none,
Residence:
c/o UBS
Financial Services, Inc., 1200 Harbor Boulevard, 5
th
Floor,
Weehawken,
NJ 07086
________________________________________________________________________________
Item
2(c). Citizenship:
Mr.
Hoekstra is a citizen of the United States.
________________________________________________________________________________
Item
2(d). Title of Class of Securities:
Common
Stock, $.01 par value
________________________________________________________________________________
Item
2(e). CUSIP Number:
44914V 10
4
________________________________________________________________________________
Item
3. If This Statement is Filed Pursuant
to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is
a:
|
|
(a)
[_] Broker or dealer registered under Section 15 of the Act (15
U.S.C. 78o);
|
|
|
(b) [_] Bank
as defined in Section 3(a)(6) of the Act (15 U.S.C.
78c);
|
|
|
(c)
[_] Insurance company as defined in Section 3(a)(19)
of the Act (15 U.S.C. 78c);
|
|
|
(d) [_] Investment company registered
under Section 8 of the Investment Company Act of 1940 (15 U.S.C.
80a-8);
|
|
|
(e)
[_] An investment adviser in accordance with §
240.13d-1(b)(1)(ii)(E);
|
|
|
(f)
[_] An employee benefit plan or
endowment fund in accordance with §
240.13d-1(b)(1)(ii)(F);
|
|
|
(g) [_] A
parent holding company or control person
in accordance with §
240.13d-1(b)(1)(ii)(G);
|
|
|
(h) [_] A
savings association as defined in Section 3(b) of
the Federal Deposit Insurance Act (12 U.S.C.
1813);
|
|
|
(i)
[_] A church plan that is excluded from the definition of
an
investment company under Section 3(c)(14) of
the Investment Company Act (15 U.S.C.
80a-3);
|
|
|
(j)
[_] Group, in accordance with §
240.13d-1(b)(1)(ii)(J);
|
|
|
(k)
[_] Group, in accordance with
'
240.13d-1(b)(1)(ii)(K).
|
If filing
as a non-U.S. institution in accordance with
'
240.13d-1(b)(1)(ii)(J), please specify the type of
institution: __________________.
CUSIP
No. 44914V
10
4 13G Page
4 of 5 Pages
Item
4. Ownership.
Provide the following information regarding the aggregate number
and percentage of the class of securities of the issuer identified in Item
1.
(a) Amount
beneficially owned:
6,124,027
SHARES (consisting of 4,159,707 shares of common stock; 1,119,538 shares
issuable upon exercise of warrants to purchase common stock; and warrants to
purchase 70,398.5 shares of preferred stock, which is convertible into 844,782
shares of common stock at the rate of 12 for one)
______________________________________________________________________
(b)
Percent of class:
Based upon
40,795,820
shares of Common Stock outstanding and 758,475 shares of convertible preferred
stock outstanding (convertible at the rate of 12 for one) on November 13, 2008,
as reported by the Issuer in its most recently filed 10-Q.
______________________________________________________________________
(c) Number
of shares as to which such person has:
(i) Sole
power to vote or to direct the vote: 6,124,027
-----------------------
(ii) Shared power to vote or to direct the vote: 0
-----------------------
(iii) Sole power to dispose or to direct the disposition of:
6,124,027
------------------
(iv) Shared
power to dispose or to direct the disposition of: 0
------------------
________________________________________________________________________________
Item
5. Ownership of Five Percent or Less of a Class.
N/A
________________________________________________________________________________
Item
6. Ownership of More Than Five Percent on Behalf of Another
Person.
N/A
________________________________________________________________________________
Item
7. Identification and Classification of the Subsidiary
Which Acquired the
Security Being Reported
on by the Parent Holding Company or Control
Person.
N/A
________________________________________________________________________________
Item
8. Identification and Classification of
Members of the Group.
N/A
________________________________________________________________________________
Item
9. Notice of Dissolution of Group.
N/A
________________________________________________________________________________
Item
10. Certifications.
(a) Not applicable
(b) Not applicable
(c) By
signing below I certify that, to the best of my knowledge and belief, the
securities referred to above were not acquired and are not held for the purpose
of or with the effect of changing or influencing the control of the issuer of
the securities and were not acquired and are not held in connection with or as a
participant in any transaction having that purpose or effect.
SIGNATURE
After
reasonable inquiry and to the best of my knowledge and belief, I certify that
the information set forth in this statement is true, complete and
correct.
|
Dated:
February 17, 2009
|
/s/ Marten
Hoekstra
|
|
Marten
Hoekstra
Hypertension Diagnositc (CE) (USOTC:HDII)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
Hypertension Diagnositc (CE) (USOTC:HDII)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025
